Benign Peripheral Nervous System Neoplasm — Variants & evidence

Benign Peripheral Nervous System Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

5 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items (5 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NF1 Loss1
Trametinib	Neurofibroma	Predictive	C	Supports Sensitivity Response	2	rejected	EID7265 A 12-year-old child with Neurofibromatosis 1 (NF1) with multiple cutaneous and paraspinal neurofibromas responsible for impaired walking, motor deficiency and pain. A treatment with Trametinib was ini… (full text at CIViC) PMID 30174724 · Papalia et al., 2018 · Open in CIViC	civic
NF1 Mutation4
Selumetinib	Plexiform Neurofibroma	Predictive	A	Supports Sensitivity Response	4	accepted	EID11176 In a pediatric phase 2 trial of the MEK inhibitor selumetinib (NCT01362803), partial responses were seen in 70% (35 of 50) children with neurofibromatosis type 1 and symptomatic inoperable plexiform n… (full text at CIViC) PMID 32187457 · Gross et al., 2020 · Open in CIViC	civic
〃	Plexiform Neurofibroma	Predictive	A	Supports Sensitivity Response	3	accepted	EID1958 Treatment with selumetinib (NCT01362803) resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofi… (full text at CIViC) PMID 28029918 · Dombi et al., 2016 · Open in CIViC	civic
〃	Plexiform Neurofibroma	Predictive	B	Supports Sensitivity Response

Data updated 9 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.